LENZ Reports $3.4 Million Q3 Revenue as VIZZ Sales Rise 50%
LENZ Therapeutics (LENZ) reported third-quarter 2026 revenue of $3.4 million and a net loss of $31.0 million, or $0.99 per basic and diluted share. VIZZ product sales were $2.6 million, up approximately 50% from the prior quarter.
The company announced a reorganization focused on consumer marketing and VIZZ commercialization, targeting 2027 operating expenses of approximately $70 million to $75 million excluding stock-based compensation. President and CEO Eef Schimmelpennink will transition from the role on December 1, with CFO Dan Chevallard appointed interim CEO.
- Q3 product sales totaled $2.6 million on more than 38,000 paid prescriptions.
- Total revenue was $3.4 million, including $0.8 million in license revenue.
- Cash, cash equivalents and marketable securities totaled $197.3 million at September 30, 2026.
- The reorganization is expected to result in about $5 million of one-time net restructuring charges.
- Telehealth contributed more than 50% of incremental Q3 prescriptions compared with Q2.
$LENZ Hedge Fund Activity
We have seen 80 institutional investors add shares of $LENZ stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC removed 1,100,148 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $6,248,840
- MILLENNIUM MANAGEMENT LLC added 639,221 shares (+73.5%) to their portfolio in Q2 2026, for an estimated $3,630,775
- QUBE RESEARCH & TECHNOLOGIES LTD added 482,195 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,738,867
- GRANAHAN INVESTMENT MANAGEMENT, LLC removed 431,100 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,448,648
- TANG CAPITAL MANAGEMENT LLC removed 414,055 shares (-47.9%) from their portfolio in Q2 2026, for an estimated $2,351,832
- ABERDEEN GROUP PLC added 391,722 shares (+33.9%) to their portfolio in Q2 2026, for an estimated $2,224,980
- MARSHALL WACE, LLP added 332,835 shares (+207.7%) to their portfolio in Q2 2026, for an estimated $1,890,502
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
